BREAST CANCER

Confirming the results of an earlier phase II study, findings from the FALCON trial showed first-line treatment with fulvestrant led to significantly better progression-free survival compared with anastrozole for patients with hormone receptor (HR)-positive advanced breast cancer.

Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the future of HER2+ breast cancer treatment.

A move by CVS Health to place in-house physician dispensaries out-of-network for purposes of Medicare Part D drug payment would force hundreds of thousands of cancer patients across the country to find alternate sources for their oral oncolytic drugs, the Community Oncology Alliance (COA) argued in a new white paper.

In a recent study, abemaciclib demonstrated clinical activity both alone and in combinations in women with HR+ metastatic breast cancer.

Erin Wysong Hofstatter, MD, associate professor at Yale Cancer Center and co-director of the Cancer Genetics and Prevention Program, discusses the actionable mutations that impact treatment and surgical decisions in breast cancer.

ASCO-CAP recently released new guidelines for the use of FISH testing for HER2 in breast cancer, due to discrepancies in HER2-testing results.

Results from the KRISTINE^ and NSABP B-41 trials provided the latest data on the use of pertuzumab, trastuzumab, ado-trastuzumab emtansine, and lapatinib for the neoadjuvant treatment of patients with HER2-positive breast cancer.

William J. Gradishar, MD, summarizes the need for new strategies to alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.

A strategy to stimulate an immune response in radiation-damaged tumor cells resulted in preliminary evidence of activity—including longer survival—in a small clinical trial of patients with metastatic breast cancer.

Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses the MERIBEL study during an interview at the 2016 ESMO Congress.

Melanie Royce, MD, details recent studies into hormone receptor-positive (HR+) and HER2-advanced breast cancer treatment.

Sara Hurvitz, MD, discusses the results from a preplanned interim analysis in HR+, HER2-negative breast cancer.

Findings of a recent multicenter randomized trial^ showed postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer (MBC) had significant slowing of disease progression with the addition of the investigational cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib to endocrine therapy.

Gabriel Hortobagyi, MD, professor of Medicine, University of Texas, MD Anderson Cancer Center, discusses the major findings of the MONALEESA-2 study in advanced breast cancer, during an interview at the 2016 ESMO Congress.

Lynette M. Sholl, MD, discusses advancements in molecular diagnostics that have led to the development of numerous single-gene assays for the detection of genetic mutations that can be targeted in the treatment of cancers.

Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center, and Co-Director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, discusses the potential role of immunotherapy in the management of breast cancer.

Hope Rugo, MD, clinical professor, department of medicine, and director of Breast Oncology Clinical Trials Program, at University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the role of immunotherapy in breast cancer.

Patricia LoRusso, DO, PhD, professor of medicine and associate director of Innovative Medicine at Yale Cancer Center, discusses the key questions that still remain regarding combination and sequencing with PARP inhibitors.

PARP inhibitors are anything but dead as breast cancer treatment, argued Patricia LoRusso, DO. 

Endocrine therapy has come a long way as a treatment for breast cancer since tamoxifen ruled the adjuvant therapy landscape in 1989, but much remains unknown about newer therapies and combating endocrine resistant mutations<br /> &nbsp;

Hope S. Rugo, MD, discusses&nbsp;immunotherapies, androgen receptor (AR)-targeted agents, and targeted therapies all on the horizon in TNBC.

Existing data for androgen receptor (AR) antagonists are encouraging and anticipated future results could soon show a benefit for these agents in large populations of patients with breast cancer.

Radiologists have been challenged by the ever-changing recommendations of when breast cancer screening should begin and the frequency of screening, says Sarah M. Friedewald, MD.&nbsp;The controversy surrounding screening recommendations can be a distraction to the implementation of new technologies, such as tomosynthesis.

Kimberly J. Van Zee, MS, MD, FACS, presented her findings on the benefits of nomogram during a panel on &ldquo;Breast Pathology for the Non-Pathologist&rdquo; at the 18^th annual Lynn Sage Breast Cancer Symposium in Chicago.<br /> &nbsp;